After a prolonged delay, Nasdaq-listed Sonnet BioTherapeutics has finally received the green light from its shareholders to move forward with a high-stakes merger. This decision opens the door to a potentially game-changing digital asset development—the creation of a $1 billion HYPE digital asset treasury.
The merger, which had been postponed several times, signals a significant pivot for Sonnet from its biotech roots toward the booming world of Web3 and tokenized assets. Shareholder approval marks a key turning point, offering renewed confidence in the company’s future direction.
Building the $1 Billion HYPE Digital Asset Treasury
At the heart of this merger is the HYPE digital asset treasury, which is expected to be valued at around $1 billion. This bold move suggests that the newly combined entity will not only engage with blockchain technology but aim to become a major player in the digital asset ecosystem.
The HYPE token, central to this vision, will likely form the backbone of treasury operations—supporting ecosystem development, strategic partnerships, and token-based incentives. The strategy signals confidence in long-term Web3 growth and could attract institutional and retail interest alike.
NEW: Nasdaq-listed Sonnet shareholders greenlight merger creating potential $1B $HYPE digital asset treasury after extended delay. pic.twitter.com/trdRas3NQ5
— Cointelegraph (@Cointelegraph) December 3, 2025
What’s Next for Sonnet and HYPE?
With the merger approved, all eyes are on execution. Investors will be watching how the company transitions into the digital asset space and whether the projected treasury value can be realized. The shift could mark one of the most ambitious transitions by a Nasdaq-listed firm into the crypto space in recent times.
As blockchain adoption accelerates across industries, the launch of the HYPE digital asset treasury positions the new entity at the intersection of traditional finance and decentralized innovation.